Ceritinib is an oral anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of ALK+ non-small cell lung cancer (NSCLC) in the United States1 and the European Union2. Here, ALK is linked to non-small cell lung carcinoma.